Total submissions: 3
            
    | Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment | 
|---|---|---|---|---|---|---|---|---|
| Labcorp Genetics | RCV001911858 | SCV002130081 | uncertain significance | not provided | 2022-08-20 | criteria provided, single submitter | clinical testing | This sequence change replaces proline, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 1759 of the MCM3AP protein (p.Pro1759Leu). This variant is present in population databases (rs201207310, gnomAD 0.03%). This variant has not been reported in the literature in individuals affected with MCM3AP-related conditions. ClinVar contains an entry for this variant (Variation ID: 1365235). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C15"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. | 
| Ambry Genetics | RCV002550972 | SCV003710883 | uncertain significance | Inborn genetic diseases | 2024-12-03 | criteria provided, single submitter | clinical testing | The c.5276C>T (p.P1759L) alteration is located in exon 24 (coding exon 24) of the MCM3AP gene. This alteration results from a C to T substitution at nucleotide position 5276, causing the proline (P) at amino acid position 1759 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. | 
| Mayo Clinic Laboratories, | RCV001911858 | SCV004225561 | uncertain significance | not provided | 2023-05-04 | criteria provided, single submitter | clinical testing | PM2 |